Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-11-16 | MDCO | Medicines Co /de | Cox Christopher T | EVP, Chief Corp. Dev. Officer | P - Purchase | $19.73 | +50,300 | 281,763 | +22% | +$992,419 | ||||||
2018-11-16 | SIGA | Siga Technologies Inc | Savas Paul G | Dir | P - Purchase | $5.58 | +5,000 | 237,847 | +2% | +$27,900 | ||||||
| DM | 2018-11-14 | TXMD | Therapeuticsmd, Inc. | Milligan John C.K. IV | Pres, Secretary | S - Sale+OE | $4.90 | -258,000 | 5,464,606 | -5% | -$1,265,232 | |||||
| D | 2018-11-16 | JNJ | Johnson & Johnson | Gorsky Alex | COB, CEO | S - Sale+OE | $145.96 | -264,465 | 338,128 | -44% | -$38,600,968 | |||||
2018-11-14 | RTRX | Retrophin, Inc. | McFarlane Neil F. | COO | S - Sale | $23.73 | -10,000 | 28,476 | -26% | -$237,314 | ||||||
| M | 2018-11-14 | RTRX | Retrophin, Inc. | Reed Elizabeth E | SVP, GC, Corporate Secretary | S - Sale | $24.03 | -5,000 | 17,827 | -22% | -$120,146 | |||||
| M | 2018-11-14 | RTRX | Retrophin, Inc. | Rote William E. | SVP, R, D | S - Sale | $24.03 | -5,000 | 17,992 | -22% | -$120,130 | |||||
| M | 2018-11-14 | RTRX | Retrophin, Inc. | Clague Laura | CFO | S - Sale | $24.02 | -7,500 | 12,033 | -38% | -$180,138 | |||||
| D | 2018-11-15 | GTHX | G1 Therapeutics, Inc. | Phillips Barclay A | SVP, CFO | S - Sale+OE | $39.92 | -5,000 | 0 | -100% | -$199,591 | |||||
| M | 2018-11-14 | RTRX | Retrophin, Inc. | Aselage Steve | CEO | S - Sale | $24.03 | -11,100 | 253,283 | -4% | -$266,703 | |||||
| D | 2018-11-14 | BMRN | Biomarin Pharmaceutical Inc | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | S - Sale+OE | $92.15 | -9,000 | 49,135 | -15% | -$829,359 | |||||
| DM | 2018-11-14 | EYEG | Eyegate Pharmaceuticals Inc | Armistice Capital, LLC | Dir, 10% | P - Purchase | $0.45 | +360,000 | 34,325,000 | +1% | +$161,395 | |||||
| D | 2018-11-14 | HZNP | Horizon Pharma Plc | Walbert Timothy P | COB, Pres, CEO | S - Sale+OE | $21.54 | -408,347 | 546,070 | -43% | -$8,795,794 | |||||
| DM | 2018-11-15 | ICPT | Intercept Pharmaceuticals, Inc. | Pruzanski Mark | Pres, CEO | S - Sale+OE | $101.07 | -50,000 | 566,805 | -8% | -$5,053,713 | |||||
| D | 2018-11-15 | FGEN | Fibrogen Inc | Rosenkranz Roberto Pedro | Dir | S - Sale+OE | $39.24 | -1,000 | 32,700 | -3% | -$39,240 | |||||
| D | 2018-11-15 | FGEN | Fibrogen Inc | Kurkijarvi Kalevi | Dir | S - Sale+OE | $39.77 | -4,000 | 23,700 | -14% | -$159,094 | |||||
| D | 2018-11-16 | CBIO | Catalyst Biosciences, Inc. | Levy Howard | Chief Medical Officer | S - Sale+OE | $11.00 | -173 | 7,560 | -2% | -$1,903 | |||||
| D | 2018-11-15 | GTHX | G1 Therapeutics, Inc. | Velleca Mark A. | Pres, CEO | S - Sale+OE | $39.84 | -5,000 | 19,000 | -21% | -$199,211 | |||||
| D | 2018-11-15 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Ch. Medical Officer, SVP R, D | S - Sale+OE | $39.75 | -3,776 | 14,700 | -20% | -$150,105 | |||||
2018-11-14 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Dir | S - Sale | $38.86 | -15,000 | 60,039 | -20% | -$582,849 | ||||||
2018-11-15 | ICUI | Icu Medical Inc/de | Pfizer Inc | Dir | S - Sale | $209.25 | -2,500,000 | 0 | -100% | -$523,125,000 | ||||||
2018-11-14 | CEMI | Chembio Diagnostics, Inc. | Potthoff John Gary | Dir | P - Purchase | $5.81 | +20,000 | 27,772 | +257% | +$116,150 | ||||||
| M | 2018-11-14 | AVEO | Aveo Pharmaceuticals Inc | Evnin Anthony B | Dir | S - Sale | $1.87 | -1,147,068 | 418,414 | -73% | -$2,140,527 | |||||
| D | 2018-11-15 | XOMA | Xoma Corp | Van Ness W Denman | Dir | S - Sale+OE | $12.67 | -5,528 | 9,275 | -37% | -$70,040 | |||||
| D | 2018-11-15 | CARA | Cara Therapeutics, Inc. | Mohindru Mani | CFO, Chief Strategy Officer | S - Sale+OE | $18.50 | -16,042 | 0 | -100% | -$296,777 | |||||
2018-11-15 | COLL | Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Dir | S - Sale | $16.60 | -25,000 | 336,000 | -7% | -$415,122 | ||||||
2018-11-15 | ENDP | Endo International Plc | Hutson Nancy J | Dir | S - Sale | $12.83 | -10,000 | 49,970 | -17% | -$128,300 | ||||||
2018-11-15 | KERX | Keryx Biopharmaceuticals Inc | Neylan John F. | Chief Medical Officer | S - Sale | $2.77 | -1,156 | 148,279 | -1% | -$3,202 | ||||||
2018-11-15 | KERX | Keryx Biopharmaceuticals Inc | Holmes Scott A | CFO | S - Sale | $2.77 | -1,155 | 162,956 | -1% | -$3,199 | ||||||
| D | 2018-11-15 | ETON | Eton Pharmaceuticals, Inc. | Casamento Charles J | Dir | P - Purchase | $6.00 | +5,000 | 68,420 | +8% | +$30,000 | |||||
| D | 2018-11-14 | AMPH | Amphastar Pharmaceuticals, Inc. | Zasloff Michael A | Dir | S - Sale+OE | $20.39 | -29,278 | 29,845 | -50% | -$596,949 | |||||
| D | 2018-11-15 | ETON | Eton Pharmaceuticals, Inc. | Brynjelsen Sean | Pres, CEO | P - Purchase | $6.00 | +10,000 | 1,034,940 | +1% | +$60,000 | |||||
| D | 2018-11-14 | AMPH | Amphastar Pharmaceuticals, Inc. | Prins Richard K | Dir | S - Sale+OE | $20.23 | -5,000 | 35,434 | -12% | -$101,167 | |||||
2018-11-14 | AMPH | Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | Pres, GC | S - Sale | $20.41 | -16,015 | 183,490 | -8% | -$326,855 | ||||||
2018-11-15 | ETON | Eton Pharmaceuticals, Inc. | Maier Paul V | Dir | P - Purchase | $6.00 | +5,000 | 59,745 | +9% | +$30,000 | ||||||
2018-11-15 | ETON | Eton Pharmaceuticals, Inc. | Riedel Norbert G | Dir | P - Purchase | $6.00 | +5,000 | 59,745 | +9% | +$30,000 | ||||||
2018-11-15 | ETON | Eton Pharmaceuticals, Inc. | Troutman William Wilson | CFO, Treasurer, Secretary | P - Purchase | $6.00 | +5,000 | 5,000 | New | +$30,000 | ||||||
2018-11-15 | ETON | Eton Pharmaceuticals, Inc. | Baum Mark L | Dir | P - Purchase | $6.00 | +10,000 | 794,745 | +1% | +$60,000 | ||||||
2018-11-15 | ACRX | Acelrx Pharmaceuticals Inc | Edwards Mark G | Dir | P - Purchase | $2.82 | +20,700 | 181,000 | +13% | +$58,376 | ||||||
2018-11-13 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | EVP, GC | S - Sale | $2.84 | -6,539 | 135,204 | -5% | -$18,571 | ||||||
2018-11-13 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $2.84 | -6,539 | 362,884 | -2% | -$18,571 | ||||||
2018-11-13 | ARDX | Ardelyx, Inc. | Kaufmann Mark | CFO | S - Sale | $2.84 | -6,539 | 146,489 | -4% | -$18,571 | ||||||
2018-11-13 | ARDX | Ardelyx, Inc. | Rosenbaum David P. | Chief Development Officer | S - Sale | $2.84 | -5,570 | 262,034 | -2% | -$15,819 | ||||||
| DM | 2018-11-13 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $3.85 | +31,314 | 35,601,800 | 0% | +$120,578 | |||||
2018-11-14 | CNCE | Concert Pharmaceuticals, Inc. | Auchincloss Thomas G | Dir | P - Purchase | $11.93 | +1,000 | 3,000 | +50% | +$11,931 | ||||||
2018-11-15 | CNCE | Concert Pharmaceuticals, Inc. | Aldrich Richard | Dir | P - Purchase | $11.83 | +50,000 | 381,326 | +15% | +$591,262 | ||||||
2018-11-13 | ALBO | Albireo Pharma, Inc. | Cooper Ronald Harold Wilfred | Pres, CEO | P - Purchase | $25.02 | +1,026 | 7,760 | +15% | +$25,668 | ||||||
2018-11-13 | XOMA | Xoma Corp | Neal James R | CEO | P - Purchase | $13.26 | +4,000 | 23,294 | +21% | +$53,056 | ||||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Kwan Rudolf | EVP, Chief Medical Officer | P - Purchase | $10.35 | +5,000 | 97,224 | +5% | +$51,748 | |||||
| DM | 2018-11-13 | PBH | Prestige Consumer Healthcare Inc. | Connors Timothy | EVP, Sales, Marketing | S - Sale+OE | $38.96 | -74,707 | 59,775 | -56% | -$2,910,902 | |||||
2018-11-13 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | P - Purchase | $11.80 | +10,000 | 2,943,633 | 0% | +$118,039 | ||||||
2018-11-12 | PCRX | Pacira Pharmaceuticals, Inc. | Wicki Andreas | Dir | S - Sale | $49.83 | -5,478 | 1,036,377 | -1% | -$272,980 | ||||||
2018-11-13 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $149.27 | -200 | 24,972 | -1% | -$29,854 | ||||||
| DM | 2018-11-12 | TXMD | Therapeuticsmd, Inc. | Finizio Robert G | CEO | S - Sale+OE | $4.77 | -184,000 | 20,393,559 | -1% | -$877,588 | |||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Lau Johnson Yiu Nam | CEO, COB, 10% | P - Purchase | $10.47 | +40,000 | 3,835,130 | +1% | +$418,800 | |||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Kwan Rudolf | EVP, Chief Medical Officer | P - Purchase | $10.49 | +10,000 | 92,224 | +12% | +$104,900 | |||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Wu Jinn | Dir | P - Purchase | $10.25 | +10,000 | 321,208 | +3% | +$102,500 | |||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Pedder Simon | See Remarks | P - Purchase | $10.26 | +2,908 | 3,908 | +291% | +$29,830 | |||||
| D | 2018-11-12 | AMRN | Amarin Corp Plcuk | Thero John F | Pres, CEO | S - Sale+OE | $19.07 | -607,611 | 2,094,528 | -22% | -$11,587,896 | |||||
| M | 2018-11-09 | CORT | Corcept Therapeutics Inc | Baker G Leonard Jr | Dir | P - Purchase | $12.95 | +200,000 | 4,866,686 | +4% | +$2,589,230 | |||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Yordon Jeffrey | See Remarks | P - Purchase | $10.49 | +9,500 | 198,209 | +5% | +$99,655 | |||||
| D | 2018-11-14 | ATNX | Athenex, Inc. | Sze Randoll | CFO | P - Purchase | $10.26 | +1,000 | 1,000 | New | +$10,255 | |||||
| M | 2018-11-12 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $14.15 | +70,200 | 9,574,861 | +1% | +$993,021 | |||||
| M | 2018-11-09 | ARPO | Aerpio Pharmaceuticals, Inc. | Hoffman Stephen J | CEO | P - Purchase | $2.01 | +31,967 | 31,967 | New | +$64,136 | |||||
2018-11-12 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $8.81 | +2,644 | 2,205,098 | 0% | +$23,286 | ||||||
2018-11-13 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $113.41 | -2,460 | 118,800,804 | 0% | -$278,979 | ||||||
2018-11-13 | PRGO | Perrigo Co Plc | Samuels Theodore R. II | Dir | P - Purchase | $65.40 | +3,500 | 11,883 | +42% | +$228,902 | ||||||
2018-11-09 | IRWD | Ironwood Pharmaceuticals Inc | Consylman Gina | CFO | S - Sale | $11.81 | -1,358 | 96,361 | -1% | -$16,038 | ||||||
| M | 2018-11-08 | PCRX | Pacira Pharmaceuticals, Inc. | Wicki Andreas | Dir | S - Sale | $51.11 | -58,245 | 1,041,855 | -5% | -$2,977,091 | |||||
| DM | 2018-11-08 | TXMD | Therapeuticsmd, Inc. | Bernick Brian | Dir | S - Sale+OE | $4.88 | -182,800 | 6,802,371 | -3% | -$891,333 | |||||
| M | 2018-11-12 | SIGA | Siga Technologies Inc | Hruby Dennis E | VP, Chief Scientific Officer | S - Sale | $5.17 | -50,000 | 197,465 | -20% | -$258,263 | |||||
2018-11-13 | TCDA | Tricida, Inc. | Parker Geoffrey M. | Chief Fin. Officer, SVP | P - Purchase | $29.72 | +5,000 | 65,000 | +8% | +$148,600 | ||||||
| M | 2018-11-09 | ITCI | Intra-Cellular Therapies, Inc. | Marcus Joel S | Dir | S - Sale | $18.17 | -32,000 | 1,291,569 | -2% | -$581,580 | |||||
| M | 2018-11-07 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.04 | +15,000 | 26,147,498 | 0% | +$589 | |||||
| M | 2018-11-08 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | EVP, Production Center | S - Sale | $20.50 | -2,173 | 157,971 | -1% | -$44,549 | |||||
| DM | 2018-11-08 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, SVP, Treasurer | S - Sale+OE | $20.74 | -38,484 | 78,152 | -33% | -$797,972 | |||||
| DM | 2018-11-08 | AMPH | Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob | SVP Corp Admin Center | S - Sale+OE | $20.97 | -17,808 | 49,131 | -27% | -$373,421 | |||||
2018-11-12 | SIGA | Siga Technologies Inc | Gomez Phillip Louis III | CEO | P - Purchase | $5.20 | +15,000 | 15,000 | New | +$78,000 | ||||||
2018-11-12 | ARDX | Ardelyx, Inc. | Sandell Scott D | 10% | S - Sale | $2.98 | -592 | 15,333,582 | 0% | -$1,767 | ||||||
| M | 2018-11-09 | XBIT | Xbiotech Inc. | McKenzie W Thorpe | Dir, 10% | P - Purchase | $3.74 | +2,900 | 3,513,000 | 0% | +$10,842 | |||||
| D | 2018-11-12 | ZTS | Zoetis Inc. | Peck Kristin C | EVP | S - Sale+OE | $94.78 | -11,500 | 33,652 | -25% | -$1,089,970 | |||||
| M | 2018-11-09 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | P - Purchase | $16.01 | +20,000 | 251,794 | +9% | +$320,211 | |||||
2018-11-09 | BLCM | Bellicum Pharmaceuticals, Inc | Stonehouse Jon P | Dir | P - Purchase | $4.56 | +10,000 | 10,000 | New | +$45,600 | ||||||
2018-11-13 | ACRX | Acelrx Pharmaceuticals Inc | Asadorian Raffi | CFO | P - Purchase | $3.13 | +5,000 | 47,000 | +12% | +$15,646 | ||||||
| M | 2018-11-07 | CKPT | Checkpoint Therapeutics, Inc. | Rosenwald Lindsay A Md | Dir | P - Purchase | $2.29 | +100,000 | 126,448 | +378% | +$229,211 | |||||
2018-11-12 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $113.48 | -202,540 | 118,803,264 | 0% | -$22,984,877 | ||||||
| DM | 2018-11-08 | BGNE | Beigene, Ltd. | Peterson Amy C. | CMO, Immuno-oncology | S - Sale+OE | $120.20 | -40,000 | 194,569 | -17% | -$4,808,089 | |||||
2018-11-09 | FLXN | Flexion Therapeutics Inc | Clayman Michael D. | Pres, CEO | P - Purchase | $17.10 | +5,000 | 796,515 | +1% | +$85,477 | ||||||
2018-11-09 | FLXN | Flexion Therapeutics Inc | Arkowitz David | CFO | P - Purchase | $16.56 | +4,000 | 48,250 | +9% | +$66,222 | ||||||
2018-11-09 | LCI | Lannett Co Inc | Crew Timothy C | CEO | P - Purchase | $5.35 | +2,000 | 41,988 | +5% | +$10,700 | ||||||
2018-11-08 | CTLT | Catalent, Inc. | Greisch John J | Dir | P - Purchase | $37.61 | +13,000 | 18,376 | +242% | +$488,930 | ||||||
| D | 2018-11-07 | TXMD | Therapeuticsmd, Inc. | Cartwright Daniel A | CFO | S - Sale+OE | $4.85 | -40,000 | 0 | -100% | -$194,000 | |||||
2018-11-09 | PRVB | Provention Bio, Inc. | Catlin Avery W | Dir | P - Purchase | $3.15 | +10,000 | 10,000 | New | +$31,500 | ||||||
2018-11-12 | SIGA | Siga Technologies Inc | Savas Paul G | Dir | P - Purchase | $5.01 | +10,000 | 232,847 | +4% | +$50,100 | ||||||
2018-11-12 | PRGO | Perrigo Co Plc | Parker Geoffrey M. | Dir | P - Purchase | $65.35 | +3,000 | 8,879 | +51% | +$196,058 | ||||||
| DM | 2018-11-08 | AMPH | Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | Pres, GC | S - Sale+OE | $20.77 | -52,296 | 199,505 | -21% | -$1,086,420 | |||||
| D | 2018-11-09 | RVNC | Revance Therapeutics, Inc. | Allouche Cyril | Principal Accounting Officer | S - Sale+OE | $23.72 | -2,188 | 4,750 | -32% | -$51,899 | |||||
2018-11-09 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $14.39 | -81,500 | 1,722,455 | -5% | -$1,172,705 | ||||||
| D | 2018-11-08 | SPPI | Spectrum Pharmaceuticals Inc | Maida Anthony E III | Dir | S - Sale+OE | $13.07 | -7,250 | 32,988 | -18% | -$94,758 | |||||
| D | 2018-11-07 | CCXI | Chemocentryx, Inc. | Schall Thomas J. | Pres, CEO | S - Sale+OE | $12.00 | -7,211 | 2,184,994 | 0% | -$86,554 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |